614 related articles for article (PubMed ID: 29716630)
1. Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study.
Marchesi F; Regazzo G; Palombi F; Terrenato I; Sacconi A; Spagnuolo M; Donzelli S; Marino M; Ercolani C; Di Benedetto A; Blandino G; Ciliberto G; Mengarelli A; Rizzo MG
J Exp Clin Cancer Res; 2018 May; 37(1):95. PubMed ID: 29716630
[TBL] [Abstract][Full Text] [Related]
2. MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index.
Due H; Brøndum RF; Young KH; Bøgsted M; Dybkær K
BMC Cancer; 2020 Mar; 20(1):237. PubMed ID: 32192453
[TBL] [Abstract][Full Text] [Related]
3. Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients.
Song G; Gu L; Li J; Tang Z; Liu H; Chen B; Sun X; He B; Pan Y; Wang S; Cho WC
Ann Hematol; 2014 Oct; 93(10):1735-43. PubMed ID: 24858372
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma.
Yang JM; Jang JY; Jeon YK; Paik JH
J Transl Med; 2018 Jun; 16(1):162. PubMed ID: 29890998
[TBL] [Abstract][Full Text] [Related]
5. Serum miR-21 predicts the prognosis of patients with primary gastrointestinal diffuse large B-cell lymphoma.
Ji Q; Jiang T; Su J; Zhang S; Li C; Yang X; Wu X; Yao J; Yuan D; Wang J
Acta Biochim Pol; 2022 Jun; 69(2):379-385. PubMed ID: 35691029
[TBL] [Abstract][Full Text] [Related]
6. miR-21 expression predicts prognosis in diffuse large B-cell lymphoma.
Li J; Fu R; Yang L; Tu W
Int J Clin Exp Pathol; 2015; 8(11):15019-24. PubMed ID: 26823838
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients.
Lim EL; Trinh DL; Scott DW; Chu A; Krzywinski M; Zhao Y; Robertson AG; Mungall AJ; Schein J; Boyle M; Mottok A; Ennishi D; Johnson NA; Steidl C; Connors JM; Morin RD; Gascoyne RD; Marra MA
Genome Biol; 2015 Jan; 16(1):18. PubMed ID: 25723320
[TBL] [Abstract][Full Text] [Related]
8. High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma.
Marques SC; Ranjbar B; Laursen MB; Falgreen S; Bilgrau AE; Bødker JS; Jørgensen LK; Primo MN; Schmitz A; Ettrup MS; Johnsen HE; Bøgsted M; Mikkelsen JG; Dybkær K
Exp Hematol; 2016 Apr; 44(4):238-46.e2. PubMed ID: 26854484
[TBL] [Abstract][Full Text] [Related]
9. Circulating exosomal microRNAs as diagnostic and prognostic biomarkers in patients with diffuse large B-cell lymphoma.
Cao D; Cao X; Jiang Y; Xu J; Zheng Y; Kang D; Xu C
Hematol Oncol; 2022 Apr; 40(2):172-180. PubMed ID: 34874565
[TBL] [Abstract][Full Text] [Related]
10. MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP.
Alencar AJ; Malumbres R; Kozloski GA; Advani R; Talreja N; Chinichian S; Briones J; Natkunam Y; Sehn LH; Gascoyne RD; Tibshirani R; Lossos IS
Clin Cancer Res; 2011 Jun; 17(12):4125-35. PubMed ID: 21525173
[TBL] [Abstract][Full Text] [Related]
11. Deregulated expression of miR-224 and its target gene: CD59 predicts outcome of diffuse large B-cell lymphoma patients treated with R-CHOP.
Song G; Song G; Ni H; Gu L; Liu H; Chen B; He B; Pan Y; Wang S; Cho WC
Curr Cancer Drug Targets; 2014; 14(7):659-70. PubMed ID: 25146331
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of hsa-miR-548d-3p and overexpression of HOXA9 in diffuse large B-cell lymphoma patients and the risk of R-CHOP chemotherapy resistance and disease progression.
Ting CY; Tan SY; Gan GG; Zain SM; Pung YF; Ong DB; Bee PC
Int J Lab Hematol; 2022 Oct; 44(5):907-917. PubMed ID: 35830966
[TBL] [Abstract][Full Text] [Related]
13. Low expression of miRNA-224 predicts poor clinical outcome in diffuse large B-cell lymphoma treated with R-CHOP.
Ni H; Wang X; Liu H; Tian F; Song G
Biomarkers; 2015; 20(4):253-7. PubMed ID: 26301883
[TBL] [Abstract][Full Text] [Related]
14. Down-regulated miR-148b increases resistance to CHOP in diffuse large B-cell lymphoma cells by rescuing Ezrin.
Sun N; Wang CY; Sun YQ; Ruan YJ; Huang YY; Su T; Zhou XH; Huang H; Guo WJ; He MQ; Yao RX; Lin XJ
Biomed Pharmacother; 2018 Oct; 106():267-274. PubMed ID: 29966970
[TBL] [Abstract][Full Text] [Related]
15. A restricted signature of serum miRNAs distinguishes glioblastoma from lower grade gliomas.
Regazzo G; Terrenato I; Spagnuolo M; Carosi M; Cognetti G; Cicchillitti L; Sperati F; Villani V; Carapella C; Piaggio G; Pelosi A; Rizzo MG
J Exp Clin Cancer Res; 2016 Jul; 35(1):124. PubMed ID: 27476114
[TBL] [Abstract][Full Text] [Related]
16. Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.
Juskevicius D; Jucker D; Klingbiel D; Mamot C; Dirnhofer S; Tzankov A
J Hematol Oncol; 2017 Mar; 10(1):70. PubMed ID: 28302137
[TBL] [Abstract][Full Text] [Related]
17. miR-199a and miR-497 Are Associated with Better Overall Survival due to Increased Chemosensitivity in Diffuse Large B-Cell Lymphoma Patients.
Troppan K; Wenzl K; Pichler M; Pursche B; Schwarzenbacher D; Feichtinger J; Thallinger GG; Beham-Schmid C; Neumeister P; Deutsch A
Int J Mol Sci; 2015 Aug; 16(8):18077-95. PubMed ID: 26251897
[TBL] [Abstract][Full Text] [Related]
18. [Significance of microRNA-146b-5p in diffuse large B-cell lymphoma and its relationship with risk assessment].
Cao QW; Li HY; Yao XX; Wang JF
Zhonghua Xue Ye Xue Za Zhi; 2012 Dec; 33(12):1010-4. PubMed ID: 23363792
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
[TBL] [Abstract][Full Text] [Related]
20. Exosome-derived miRNAs as predictive biomarkers for diffuse large B-cell lymphoma chemotherapy resistance.
Feng Y; Zhong M; Zeng S; Wang L; Liu P; Xiao X; Liu Y
Epigenomics; 2019 Jan; 11(1):35-51. PubMed ID: 30211623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]